(NASDAQ: HBIO) Harvard Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 96.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 1,605.68%.
Harvard Bioscience's earnings in 2026 is -$11,804,000.On average, 4 Wall Street analysts forecast HBIO's earnings for 2026 to be -$2,892,016, with the lowest HBIO earnings forecast at -$2,778,603, and the highest HBIO earnings forecast at -$2,977,075.
In 2027, HBIO is forecast to generate $3,008,629 in earnings, with the lowest earnings forecast at $1,658,199 and the highest earnings forecast at $4,417,595.